back to US directory
us clinical guidance

Cellulitis and erysipelas

US distinction of nonpurulent cellulitis from abscess, severity assessment, focused microbiology and necrotizing-infection escalation.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Children and adults with diffuse nonpurulent bacterial infection of skin and subcutaneous tissue. Purulent collections, surgical-site infection, diabetic foot infection, animal or human bites, periorbital disease, immersion injury and profound immunocompromise require separate source-specific decisions. The underlying IDSA guideline is older but remained listed in the current IDSA guideline directory at the source check.
sources for this section:IDSA SSTI 2014

The Bottom Line

  • Distinguish nonpurulent spreading erythema, warmth, edema and tenderness from an abscess or another purulent focus because drainage, not simply broader antibiotics, is central when pus is present.
  • Typical nonpurulent cellulitis should receive streptococcal-active treatment; add methicillin-resistant Staphylococcus aureus coverage only for defined risk factors, penetrating trauma, purulence or severe infection.
  • Do not routinely culture blood, aspirate or biopsy in a typical uncomplicated case; obtain microbiology when systemic toxicity, immunocompromise, unusual exposure or treatment failure makes the result actionable.
  • Elevate the affected limb where feasible and treat portals and predisposing conditions such as edema, toe-web fissures or dermatosis to improve recovery and reduce recurrence.
sources for this section:IDSA SSTI 2014

Practical clinical workflow

1
Record tempo, pain, fever, trauma, bite, water exposure, injection, surgery, previous MRSA, diabetes, edema, venous disease and immune status; examine the entire limb and regional nodes.
2
Mark or photograph the margin with consent, assess hemodynamics and organ function, look for fluctuance, crepitus, bullae and pain beyond visible erythema, and identify the likely entry site.
3
Select oral or parenteral therapy according to severity, likely pathogens, local resistance, allergy and ability to absorb medication; avoid unnecessarily broad gram-negative or anaerobic coverage in a typical case.
4
Review early progression and systemic response, recognizing that inflammation can transiently appear worse; lack of meaningful improvement should trigger diagnostic review, imaging or source control as indicated.
sources for this section:IDSA SSTI 2014

Safety boundaries and escalation

  • Pain out of proportion, rapidly advancing edema, hemorrhagic bullae, skin anesthesia, crepitus, systemic shock or organ dysfunction requires immediate surgical evaluation for necrotizing infection.
  • Orbital symptoms, facial infection with ocular findings, hand deep-space infection, infected prosthesis or suspected septic arthritis requires an anatomic specialist pathway rather than routine cellulitis care.
  • A venous thrombosis, stasis dermatitis, gout, contact dermatitis and inflammatory edema can mimic cellulitis; bilateral lower-leg redness should prompt deliberate reconsideration before antibiotics.
  • Recurrent episodes require evaluation of edema, lymphatic damage, obesity, skin disease and toe-web abnormalities; repeated empiric antibiotics without prevention planning is incomplete care.
sources for this section:IDSA SSTI 2014

Localization

US empiric therapy should reflect the local antibiogram, community MRSA epidemiology and hospital severity pathway. This page independently summarizes the still-listed 2014 IDSA source and awaits infectious-disease review.
sources for this section:IDSA SSTI 2014

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Infectious Diseases Society of AmericaPractice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 UpdateDOI 10.1093/cid/ciu296; correction DOI 10.1093/cid/civ114 路 published 2014-07-15 路 updated 2015-05-01 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.